Ashvattha Therapeutics Unveils Transformative Dendrimer-based anti-VEGF Treatment for Retinal Diseases at ARVO 2020
May 6, 2020
Company to develop subcutaneously administered dendrimer-based anti-VEGF therapy with selective targeting in wet AMD. Potential therapeutic may offer significant opportunities for degenerative retinal diseases such as wet AMD and diabetic retinopathy, and may reduce significant side effects associated with systemic treatment of ocular disease.